## Claims:

A method of treating an LFA-1 or a TNF- $\alpha$  mediated disorder, comprising administering to a mammal in need thereof effective amounts of an LFA-1 antagonist and a TNF- $\alpha$  antagonist.

- 2. A method of treating cantilage damage from injury or preventing initial or continued damage by a degenerative cartilagenous disorder or injury, comprising contacting the cartilage with effective amounts of an LFA-1 antagonist and a TNF- $\alpha$  antagonist.
- 3. The method of claim 1 or 2, wherein the disorder is a degenerative cartilagenous disorder.
- 4. The method of claim 3, wherein the degenerative cartilagenous disorder is selected from the group consisting of rheumatoid arthritis and osteoarthritis.
- 5. The method of one of claims 1-4, wherein the LFA-1 antagonist is an anti-LFA-1 antibody, preferably an anti-CD11a antibody.
- 6. The method of one of claims 1-5, wherein the LFA-1 antagonist is a non T-cell depleting anti-CD11a antibody.
- 7. The method of one of claims 1-6, wherein the TNF- $\alpha$  antagonist is an immunoadhesin.
- 8. The method of one of claim  $\sqrt[7]{7}$  wherein the immunoadhesin is a fusion of at least a portion of a TNF- $\alpha$  binding protein and a portion of an immunoglobulin.
- 9. The method of one of claim  $8^{\checkmark}$ , wherein the TNF- $\alpha$  binding protein is a TNF- $\alpha$  receptor IgG Fc fusion protein.
- 10. A composition, comprising an LFA-1 antagonist and a TNF-α antagonist.
- 11. The composition of claim 10, wherein the LFA-1 antagonist is an anti-LFA-1 antibody
- 12. The composition of claim 11, wherein the anti-LFA-1 antibody is an anti-CD11a antibody.
- 13. The composition of claim 12, wherein the an anti-CD11a antibody is a non T-cell depleting antibody.
- 14. The composition of claim 10, wherein the TNF- $\alpha$  antagonist is an immunoadhesin.
- 15. The composition of claim 14, wherein the immunoadhesin is a fusion of at least a portion of a TNF- $\alpha$  binding protein and a portion of an immunoglobulin.
- 16. The composition of claim 15, wherein the TNF- $\alpha$  binding protein is a TNF- $\alpha$  receptor IgG Fc fusion protein.

att 7

# 83532